Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 15/20 | 1.00 |
| ▸ | FEN1 | P39748 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.60 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.60 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31741258 | 1.00 | DAO (1.00) | DAOFEN1CA12RNASEH1ERCC1 | |
| SCHEMBL7349965 | 0.79 | DAO (0.66) | DAOFEN1CA12RNASEH1ERCC1 | |
| SCHEMBL12801790 | 0.78 | DAO (0.64) | DAOFEN1CA12RNASEH1ERCC1 | |
| SCHEMBL29991182 | 0.76 | DAO (0.61) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL29933774 | 0.75 | FEN1 (1.00) | DAOFEN1CA12RNASEH1ERCC1 | |
| SCHEMBL1520708 | 0.75 | FEN1 (1.00) | DAOFEN1CA12RNASEH1ERCC1 | |
| SCHEMBL29934205 | 0.75 | DAO (0.60) | DAOFEN1CA12RNASEH1ERCC1 | |
| SCHEMBL11431122 | 0.75 | DAO (0.60) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL4558163 | 0.75 | DAO (0.60) | DAOFEN1CA12RNASEH1ERCC1 | |
| SCHEMBL981536 | 0.74 | DAO (0.59) | DAOPOLBMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6048900-A | FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA | BAYER CORPORATION (US) | 2000-04-11 | — | — | US | claimed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-06 | — | — | US | disclosed |
| US-8362270-B2 | Self-assembled nanostructures | XEROX CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110282072-A1 | SELF-ASSEMBLED NANOSTRUCTURES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-11-17 | — | — | US | disclosed |
| US-8025723-B2 | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments | XEROX CORPORATION (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100300326-A1 | NONPOLAR LIQUID AND SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2008154905-A2 | MODIFICATIONS OF THE HISTONE DEACETYLASE INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID | SCHEBO BIOTECH AG (DE) | 2008-12-24 | — | — | WO | disclosed |
| US-6410792-B1 | OBESITY DISEASES | BAYER CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6048900-A | FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA | BAYER CORPORATION (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282072-A1 | SELF-ASSEMBLED NANOSTRUCTURES | RB1, CNKSR1, RBBP4 | DAO 4306/4885FEN1 3652/4885CA12 2930/4885 |
| US-20150218156-A1 | INHIBITORS OF D-AMINO ACID OXIDASE | DDO, DAO, GRIN2A | DAO 2/4885FEN1 4265/4885CA12 2866/4885 |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | DAO 1402/4885FEN1 3082/4885CA12 1553/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | DAO 1392/4885FEN1 3058/4885CA12 1508/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | DAO 1402/4885FEN1 3082/4885CA12 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.